Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who fail venetoclax-based salvage therapies, commenting on poor prognosis. Dr Zucenka reports that venetoclax re-initiation or low-dose cytarabine plus glasdegib may be possible options for patients in this subgroup. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

свернуть